Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Blood

Volumn 100, Issue 9, 2002, Pages 3141-3146

  Avvisati, Giuseppe ^a   Petti, Maria Concetta ^b   Lo Coco, Francesco ^c   Vegna, Maria Luce ^d   Amadori, Sergio ^e   Baccarani, Michele ^f   Cantore, Nicola ^g   Bona, Eros Di ^h   Ferrara, Felicetto ⁱ   Fioritoni, Giuseppe ^j   Gallo, Eugenio ^j   Invernizzi, Rosangela ^k   Lazzarino, Mario ^l   Liso, Vincenzo ^m   Mariani, Guglielmo ⁿ   Ricciuti, Francesco ^o   Selleri, Carmine ^p   Sica, Simona ^a   Veneri, Dino ^a   Mandelli, Franco ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h Ospedale Civile di Pescara   (Italy)

ⁱ MOLINETTE HOSPITAL   (Italy)

^j UNIVERSITY OF PAVIA   (Italy)

^k POLICLINICO   (Italy)

^l UNIVERSITY OF PALERMO   (Italy)

^m SAN CARLO HOSPITAL   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o CATHOLIC UNIVERSITY   (Italy)

^p UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; TIOGUANINE;

ADULT; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED DISEASE; DRUG INFUSION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; VOMITING;

EID: 0036838645     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0352     Document Type: Article

References (26)

1. Avvisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: Clinical and morphologic features and prognostic factors. Semin Hematol. 2001;38:4-12.
2. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol. 2001;38:13-25.
3. Fenaux P, Chastang C, Sanz MA, et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94: 1192-1200.
4. Tallman MS, Andersen JW, Schiffer CA, et al. Alltrans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
5. Asou N, Adachi J, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;16: 78-85.
6. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial. Blood. 1999;80:582-586.
7. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: Results of treatment with daunorubicin. Blood. 1973;41:489-496.
8. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukaemia. Blood. 1995;86:1717-1728.
9. von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. Am J Med. 1997;62:200-208.
10. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol. 1997;15: 1544-1552.
11. Avvisati G, Mandelli F, Petti MC, et al. Idarubicin (4-demethoxidaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA. Eur J Haematol. 1990;44:257-260.
12. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A GIMEMA pilot study. Blood. 1996;88:1390-1398.
13. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90: 1014-1021.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British cooperative group. Ann Intern Med. 1985;103:620-625.
15. Kaplan EL, Meier P, Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient, II: Analysis and examples. Br J Cancer. 1977;35:1-39.
17. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187-220.
18. Mandelli F, Petti MC, Avvisati G, et al. GIMEMA experience in the treatment of adult acute myelogenous leucemia. In: Gale R, ed. Acute Myelogenous Leukemia: Progress and Controversies. New York, NY: Wiley-Liss: 1990;273-291.
19. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
20. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol. 1995;13:2827-2834.
21. Marty M, Ganem G, Fischer J, et al. Leucémie aigue promyélocitaire: Étude retrospective de 119 malades traites par daunorubicine. Nouv Rev Fran Hematol. 1984;26:371-378.
22. Petti MC, Avvisati G, Amadori S, et al. Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients. Haematologica. 1987;72:151-155.
23. Sanz MA, Jarque I, Martin G, et al. Acute promyelocytic leukemia: Therapy results and prognostic factors. Cancer. 1988;61:7-13.
24. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997;15:483-490.
25. Sanz MA, Martin G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
26. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia. 1994;8: 968-973.